
News|Articles|February 13, 2019
Daurismo for Newly Diagnosed AML
Author(s)Drew Boxler
Advertisement
Daurismo (glasdegib, Pfizer)
Indications: Newly-diagnosed acute myeloid leukemia (AML) in adult patients who are 75 years old or older and have comorbidities that preclude use of intensive induction chemotherapy
Dosage: 100 mg orally, once daily.
Contraindications: None
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Post-Pandemic Vaccine Gaps Mirror Socioeconomic Disparities
2
FDA Approves Gwyn Lo, a Once Weekly Low-Dose Estrogen Contraceptive Patch
3
Study Links GLP-1s to Lower Fragility Fractures in Adults With Diabetes
4
FDA Approves First-in-Class Centanafadine for Treatment of ADHD
5






























